OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

Posted by Defense World Staff on Aug 10th, 2024

Analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.

A number of other analysts have also weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $4.25 target price on shares of OncoCyte in a research note on Friday. Stephens reissued an “equal weight” rating and issued a $4.00 price objective on shares of OncoCyte in a research report on Wednesday, April 17th. Finally, Benchmark reaffirmed a “speculative buy” rating and set a $5.00 price objective on shares of OncoCyte in a research report on Monday, April 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.06.

View Our Latest Research Report on OCX

OncoCyte Stock Performance

Shares of OncoCyte stock opened at $3.12 on Friday. OncoCyte has a 1-year low of $2.08 and a 1-year high of $4.34. The stock’s 50 day simple moving average is $2.97 and its 200-day simple moving average is $2.92.

OncoCyte (NASDAQ:OCX – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. OncoCyte had a negative net margin of 2,905.14% and a negative return on equity of 135.45%. The company had revenue of $0.10 million during the quarter. On average, equities analysts expect that OncoCyte will post -2.58 EPS for the current year.

OncoCyte Company Profile

(Get Free Report)

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.